Last Updated: August 9, 2026

Bulk Pharmaceutical API Sources for ESKALITH CR

✉ Email this page to a colleague

Bulk Pharmaceutical API Sources for ESKALITH CR

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory	⤷ Start Trial	qGcHaXxEpEvxsYRXF`@	⤷ Start Trial
MP Biomedicals	⤷ Start Trial	212612	⤷ Start Trial
NovoSeek	⤷ Start Trial	11125	⤷ Start Trial
NovoSeek	⤷ Start Trial	516884	⤷ Start Trial
MP Biomedicals	⤷ Start Trial	152537	⤷ Start Trial
TCI (Tokyo Chemical Industry)	⤷ Start Trial	L0224	⤷ Start Trial
MolPort	⤷ Start Trial	MolPort-003-927-648	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.